Tryptophan catabolism in *Pseudomonas aeruginosa* and potential for inter-kingdom relationship

Perrine Bortolotti¹, Benjamin Hennart², Camille Thieffry¹, Guillaume Jausions¹, Emmanuel Faure¹, Teddy Grandjean³, Marion Thepaut³, Rodrigue Dessein³, Delphine Allorge², Benoit P. Guery⁴, Karine Faure³, Eric Kipnis³, Bertrand Toussaint⁵,⁶ and Audrey Le Gouellec⁵,⁶*

**Abstract**

**Background:** *Pseudomonas aeruginosa* (Pa) is a Gram-negative bacteria frequently involved in healthcare-associated pneumonia with poor clinical outcome. To face the announced post-antibiotic era due to increasing resistance and lack of new antibiotics, new treatment strategies have to be developed. Immunomodulation of the host response involved in outcome could be an alternative therapeutic target in *Pa*-induced lung infection. Kynurenines are metabolites resulting from tryptophan catabolism and are known for their immunomodulatory properties. *Pa* catabolizes tryptophan through the kynurenine pathway and are known for their immunomodulatory properties. *Pa* catabolizes tryptophan through the kynurenine pathway. Interestingly, many host cells also possess the kynurenine pathway, whose metabolites are known to control immune system homeostasis. Thus, bacterial metabolites may interfere with the host’s immune response. However, the kynurenine pathway in *Pa*, including functional enzymes, types and amounts of secreted metabolites remains poorly known. Using liquid chromatography coupled to mass spectrometry and different strains of *Pa*, we determined types and levels of metabolites produced by *Pa* ex vivo in growth medium, and the relevance of this production in vivo in a murine model of acute lung injury.

**Results:** Ex vivo, *Pa* secretes clinically relevant kynurenine levels (µM to mM). *Pa* also secretes kynurenic acid and 3-OH-kynurenine, suggesting that the bacteria possess both a functional kynurenine aminotransferase and kynurenine monooxygenase. The bacterial kynurenine pathway is the major pathway leading to anthranilate production both ex vivo and in vivo. In the absence of the anthranilate pathway, the kynurenine pathway leads to kynurenic acid production.

**Conclusion:** *Pa* produces and secretes several metabolites of the kynurenine pathway. Here, we demonstrate the existence of new metabolic pathways leading to synthesis of bioactive molecules, kynurenic acid and 3-OH-kynurenine. The kynurenine pathway in *Pa* is critical to produce anthranilate, a crucial precursor of some *Pa* virulence factors. Metabolites (anthranilate, kynurenine, kynurenic acid) are produced at sustained levels both ex vivo and in vivo leading to a possible immunomodulatory interplay between bacteria and host. These data may imply that pulmonary infection with bacteria highly expressing the kynurenine pathway enzymes could influence the equilibrium of the host’s tryptophan metabolic pathway, known to be involved in the immune response to infection. Further studies are needed to explore the effects of these metabolic changes on the pathophysiology of *Pa* infection.

**Keywords:** *Pseudomonas aeruginosa*, Kynurenine, Kynurenic acid, Tryptophan, Anthranilate

* Correspondence: alegouellec@chu-grenoble.fr

¹Laboratoire TIMC-TheREx (UMRSS25 CNRS-UGA) Université Grenoble Alpes, Faculté de médecine, La Tronche, France

²Unité médicale de Biochimie des enzymes et des protéines, CHUGA de Grenoble, CS10207, Grenoble 38043, Rhone alpes, France

Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
**Background**

*Pseudomonas aeruginosa* (Pa) is a Gram-negative bacterium frequently involved in healthcare-associated pneumonia and as an opportunistic pathogen in immunocompromised patients [1]. Given its increasing acquired resistance to antibiotics and capacity to adapt to host defenses, Pa-induced infections are associated with poor clinical outcome [2]. A better understanding of the metabolic pathways supporting virulence may lead to development of innovative therapeutic strategies [1, 3]. Pa belongs to the limited group of pathogens able to metabolize tryptophan into anthranilate through the oxidative kynurenine pathway [2, 4]. Because kynurenine and derivatives are also established bioactive metabolites in humans [5], their bacterial secretion in the microenvironment could play a role in the bacteria-host relationship. Furthermore, anthranilate is a crucial precursor for the Pseudomonas Quinolone Signal (PQS), a signaling molecule of the quorum-sensing system regulating the expression of several virulence factors [6, 7]. Thus, establishing the complete pathways of prokaryotic tryptophan metabolites production during bacterial growth appears necessary from a physiopathological standpoint. Bacteria from the Pseudomonas genus degrade kynurenine either through the kynurenine pathway leading to anthranilate or through the quinolinine pathway, leading to kynurenic acid [8]. In addition, some strains of *Pseudomonas fluorescens* possess a kynurenine monooxygenase (KMO) responsible for 3-OH-kynurenine production [8, 9]. To date, the three known enzymes composing the kynurenine pathway in *Pa* are tryptophan-2,3-dioxygenase (encoded by *kynA*), kynurenine formamidase (encoded by *kynB*), and kynureninase (encoded by *kynU*), leading respectively to formylkynurenine, kynurenine and anthranilate production (Fig. 1) [4, 10]. However, the concentration range and kinetics of kynurenine production during bacterial growth are poorly known. In addition, whether Pa is able to produce kynurenic acid and 3-OH-kynurenine remains unclear. It is currently thought that the Pa kynurenine pathway only leads to anthranilate [11]. Anthranilate either results from the conversion of chorismate by anthranilate synthases, or from the degradation of tryptophan via the kynurenine pathway, which is considered to be the predominant pathway for anthranilate synthesis in rich growth medium [12, 13]. However, quantitative assessment of anthranilate production through this pathway has never been performed in Pa. Furthermore, whether the kynurenine pathway remains the major source of anthranilate in vivo during infection has never been studied to date. The following experiments aim to determine tryptophan metabolites and their production levels ex vivo during *Pa* growth in rich medium using wild type strain CHA, and Δ*kynA* or Δ*kynU* deletion mutants. We also assessed kynurenine pathway metabolites production in vivo in a murine model of acute lung injury.

**Results**

As a preliminary experiment, we compared bacterial growth ex vivo in non-renewed LB medium between wild type and mutant strains, to assess the fitness of mutant strains. Bacterial growth was identical for each strain, strongly suggesting that bacterial fitness is similar (Table 1).

*The kynurenine pathway in Pa produces high-level anthranilate ex vivo*

To explore the ability of *Pa* to produce anthranilate, we assessed concentrations of tryptophan, kynurenine and anthranilate production (Fig. 1) [4, 10]. However, the concentration range and kinetics of kynurenine production during bacterial growth are poorly known. In addition, whether Pa is able to produce kynurenic acid and 3-OH-kynurenine remains unclear. It is currently thought that the *Pa* kynurenine pathway only leads to anthranilate [11]. Anthranilate either results from the conversion of chorismate by anthranilate synthases, or from the degradation of tryptophan via the kynurenine pathway, which is considered to be the predominant pathway for anthranilate synthesis in rich growth medium [12, 13]. However, quantitative assessment of anthranilate production through this pathway has never been performed in *Pa*. Furthermore, whether the kynurenine pathway remains the major source of anthranilate in vivo during infection has never been studied to date. The following experiments aim to determine tryptophan metabolites and their production levels ex vivo during *Pa* growth in rich medium using wild type strain CHA, and Δ*kynA* or Δ*kynU* deletion mutants. We also assessed kynurenine pathway metabolites production in vivo in a murine model of acute lung injury.
anthranilate during bacterial growth (i.e. H4, H6, H8 and H24) in non-renewed LB growth medium of \( \text{P. aeruginosa} \) strains using an UPLC-MS/MS system. To investigate the role of the kynurenine pathway in anthranilate production, we assessed metabolite concentrations in growth medium of CHA, compared with \( \text{kynA} \) gene deleted strain lacking tryptophan-2,3-dioxygenase (CHA\(^{Δ} \text{kynA}\)) theoretically unable to produce kynurenines, and a \( \text{kynU} \) gene deleted strain (CHA\(^{Δ} \text{kynU}\)), lacking kynureninase, unable to degrade kynurenines and theoretically overproducing them via the KynR-positive transcriptional loop [11]. We show that \( \text{P. aeruginosa} \) (strain CHA) is able to produce anthranilate ex vivo from 4 h of culture and anthranilate accumulates until 100 \( \mu \text{M} \) concentration after 24 h of culture for a bacterial count of 2.10\(^9 \) CFU/ml (Fig. 2). This production is impaired when the \( \text{kynA} \) or \( \text{kynU} \) genes are deleted, leading to a hundred-fold decrease in metabolite concentrations at 24 h. During the first 8 h, tryptophan concentration is stable then decreases in supernatant for CHA strain, but in a lesser extent in CHA\(^{Δ} \text{kynU}\) and not in CHA\(^{Δ} \text{kynA}\). The stability of tryptophan concentrations over 24 h in CHA\(^{Δ} \text{kynA}\) growth medium compared with the hundred-fold decrease observed with the wild type strain confirm the essential role of the kynurenine pathway in tryptophan catabolism, given that both strains have the same ability to synthesize tryptophan.

**Pa is able to produce kynurenic acid**

We aimed to determine whether \( \text{P. aeruginosa} \) was able to produce kynurenic acid during growth in rich medium. Using the same protocol, we assessed kynurenic acid concentrations in culture supernatants of CHA, CHA\(^{Δ} \text{kynA}\) and CHA\(^{Δ} \text{kynU}\) strains at H4, H6, H8 and H24. CHA produces kynurenic acid at \( \mu \text{M} \) levels, at inoculum identical to those above (Fig. 3). Conversely, CHA\(^{Δ} \text{kynA}\) is unable to produce kynurenic acid, whereas CHA\(^{Δ} \text{kynU}\) overproduces it, reaching 100 \( \mu \text{M} \) at H24. This overproduction of kynurenic acid by CHA\(^{Δ} \text{kynU}\), taken together with the ten-fold decrease in tryptophan concentration in CHA\(^{Δ} \text{kynU}\) growth medium at 24 h compared to initial tryptophan concentration, suggests that an additional enzymatic pathway is involved in tryptophan degradation when kynureninase is lacking.

These results strongly suggest that \( \text{P. aeruginosa} \) possesses a functional kynurenine aminotransferase (KAT), leading to kynurenic acid production. In addition, the kynurenic acid pathway seems to be the major pathway for tryptophan catabolism when kynureninase function is impaired. Last, these results prove specifically in \( \text{P. aeruginosa} \), that both the anthranilate and the kynurenic acid pathways coexist.

**Pa is able to produce 3-OH-kynurenine**

We aimed to determine whether \( \text{P. aeruginosa} \) was able to produce 3-OH-kynurenine. We quantified 3-OH-kynurenine in supernatants of growth culture of CHA, CHA\(^{Δ} \text{kynA}\) and

---

**Table 1** Bacterial growth assessment of CHA strain and mutants

|                | CHA  | CHA\(^{Δ} \text{kynU}\) | CHA\(^{Δ} \text{kynA}\) |
|----------------|------|------------------------|------------------------|
| Qx expo (h\(^{-1}\)) | 1.29 | 1.22                   | 1.34                   |
| Generation time (min) | 32   | 34                     | 31                     |

Qx expo refers to the growth rate during exponential growth (h\(^{-1}\)).
Generation time refers to the doubling time of bacterial population during the exponential phase of growth (minutes). One experiment representative of three

---

Fig. 2 Tryptophan, anthranilate, and L-kynurenine concentrations ex vivo. Tryptophan, anthranilate, and L-kynurenine concentrations in growth medium supernatants of CHA strain (black), CHA\(^{Δ} \text{kynA}\) strain (dark gray) and CHA\(^{Δ} \text{kynU}\) strain (light gray) as determined by UPLC-MS-MS. All data from two experiments in duplicates. Error bars represent means +/- SD.
CHAΔkynU strains at H6, H8 and H24 (Fig. 4). Concentrations of 3-OH-kynurenine in CHAΔkynU growth medium reached 10 μM at H24. As CHAΔkynU cannot catabolize kynurenine and the production of 3-OH-kynurenine increases in that mutant, these results strongly suggest that Pa possesses a functional KMO.

The kynurenic acid pathway is critical for anthranilate production in vivo

In an ex vivo model of non-renewed growth culture medium, we show that the kynurenic acid pathway leads to anthranilate synthesis at high concentrations, and to kynurenic acid production to a lesser extent. In vivo during pneumonia, both the infected host and the bacteria can produce anthranilate and its metabolites through the kynurenic acid pathway. In this study, we sought to determine the role of the bacterial kynurenine pathway in anthranilate synthesis in vivo in a murine model of acute lung injury. After a 12-hour or a 24-hour acute lung infection induced with CHA, CHAΔkynA or CHAΔkynU strain, mice were sacrificed and bronchoalveolar lavages were performed. Using UPLC-MS/MS, we assessed anthranilate and 3-OH-anthranilate concentrations in BAL (Fig. 5). Anthranilate concentrations were under the detection threshold in the three groups. However, 3-OH-anthranilate was detected in BAL from mice infected with the CHA strain, whereas 3-OH-anthranilate was undetectable in BAL supernatants from
mice infected with either CHADkynA or CHADkynU strains, with detection and quantification limits of respectively 0.5 and 10 nmol/L. As 3-OH-anthranilate directly comes from anthranilate metabolism, this result strongly supports the critical involvement of the bacterial kynurenine pathway in anthranilate production during Pa-induced acute lung infection.

The kynurenine pathway leads to kynurenic acid production in vivo
Using the same murine model, we assessed kynurenic acid concentrations in BAL in a 12-hour and 24-hour acute lung infections with CHA, CHADkynA or CHADkynU strains (Fig. 6). The detection and quantification limits for kynurenic acid were respectively 0.5 and 10 nmol/L. Kynurenic acid concentrations were significantly increased in BAL of CHADkynU infected mice compared with the two other groups at H12. In addition, kynurenic acid concentrations were under the detection threshold in CHADkynA induced infection. These results suggest that the bacterial kynurenine pathway leads to significant kynurenic acid production in vivo at H12 post infection.

Bacterial metabolites of the quinolinine pathway may interfere with the outcome of infection
When assessing virulence of each strain through survival of mice during acute lung infection, we showed a trend toward decreased survival in mice infected with CHADkynU strain compared to those infected with CHADkynA strain ($p = 0.063$) (Fig. 7). This result may suggest that kynurenic pathway metabolites could be involved in virulence during acute lung infection. There was no statistically significant difference in survival of mice between strains CHA and CHADkynA ($p = 0.15$), and between strains CHA and CHADkynU ($p = 0.57$) respectively.

Discussion
Unlike most bacteria catabolizing tryptophan anaerobically into indole pyruvate and ammonia [14], Pa degrades tryptophan through the oxidative kynurenine pathway [15]. The initial step of this pathway is performed by the tryptophan-2,3-dioxygenase, leading to kynurenine synthesis [4]. Previous studies in other organisms or in humans have shown that kynurenine could be catabolized either into kynurenic acid through a KAT, or into anthranilate through a kynureninase [8]. The kynurenine pathway genotype varies with bacterial strains and
enzymatic activity depends on growth conditions [8, 16]. In this study, we focused on the potential for cross-talk between host cells and Pa. Therefore, we assessed secreted metabolites concentrations in growth medium and not in bacterial lysates. A limitation to our study resides in the possibility that concerning the non-detection of some metabolites one cannot affirm an absence of their production since rapid metabolism or non-secretion could be responsible for low levels.

We demonstrate the ability of Pa to secrete different tryptophan catabolites from the kynurenine pathway in its environment both ex vivo during growth and in vivo during lung infection (Fig. 8).

Using comparative genomics, Kurnasov et al. reported that Pa possesses the genes encoding for the enzymes of the anthranilate pathway, but the authors did not identify genetic support for a quinolinate enzymatic pathway allowing kynurenic acid synthesis [17]. In our study, we show for the first time that Pa is able to produce kynurenic acid during growth in rich medium. When kynUl encoding for kynureninase is lacking, CHAΔkynU produces a large amount of kynurenic acid whereas anthranilate concentration remains stable. Conversely, no kynurenic acid was detected in CHAΔkynA growth medium. A hypothetic pathway involving a reaction between anthranilate and orotic acid to form kynurenic acid has already been invalidated [18]. Taken together, these results suggest that Pa expresses a functional KAT, as hypothesized previously for other species of Pseudomonas genus bacteria [8, 16]. The identification of KAT homologues in E. coli, the hyperthermophilic archaeon Pyrococcus horikoshii and human prompted us to search for a homologue in Pa [19–21]. Searches using BlastP on Pseudomonas.com with these KAT sequences give several hits. The best match originating from P. aeruginosa was from the open reading frame PA3798 (ybdL). We also found with lower BLAST scores GntR (PA2320) and PhhC (PA0870), an essential amino-transferase for aromatic amino acid catabolism.

However, the difference between anthranilate and kynurenic acid concentrations suggests that the kynurenine pathway mostly leads to anthranilate production in our ex vivo growth conditions. The absence of sustained increase in anthranilate concentration levels over time after H4 in CHAΔkynA and CHAΔkynU growth media supports this hypothesis. Our results are consistent with previously published data asserting that the kynurenine pathway serves as a critical source of anthranilate in rich medium [13]. The initial ten-fold increase in anthranilate concentration observed for both CHAΔkynU and CHAΔkynA strains suggests the potential involvement of another minor enzymatic pathway for anthranilate synthesis.

The detection of 3-OH-kynurenine in CHAΔkynU growth medium, but not in CHAΔkynA growth medium...
suggests that *Pa* is able to convert kynurenine into 3-OH-kynurenine, possibly through a KMO. As for the quinolinine enzymatic pathway, to this date no KMO gene has been identified in the *Pa* genome [17]. As mentioned with KAT search, we used KMO sequence from *Pseudomonas fluorescens* strain 17400 (K84HFS) that has 36 % identity and 54 % homology with human KMO, and was experimentally proved as a KMO [9]. We found several hits as PA4190 (PqsL) with 28 % identity on 394 amino acid sequence length and PA3328 a probable FAD-dependent monoxygenase with 26 % identity. This % of identity is not so high considering the species and further experimental researches should be done.

Here we show that *Pa* is able to produce and secrete kynurenine, kynurenic acid and anthranilate at clinically relevant levels (µM to mM) ex vivo in rich medium. We find the same profile of metabolites production using another clinical strain (Additional file 1). Rich medium seems to be the best ex vivo model to simulate the in vivo bacterial growth conditions, as sputum from the lungs of cystic fibrosis patients are rich in amino-acids and form a carbon source to support the growth of *Pa* [22]. Further studies are needed in other rich media such as sputum simulation media or clinical sputum samples to better understand the bacterial kynurenine metabolism in vivo.

In vivo, we confirm that the kynurenine pathway is critical for anthranilate production. The increase in 3-OH-anthranilate levels only detected in BAL supernatants from infected mice with CHA strain shows that the bacterial kynurenine pathway is a clinically relevant pathway for anthranilate synthesis in vivo. This result is consistent with the hypothesis of Farrow et al. who speculate that the kynurenine pathway may be particularly important to support PQS production in rich tryptophan environment [13]. In the absence of this anthranilate pathway, infection is associated with kynurenic acid production. The early increase in kynurenic acid in BAL at H12 but not H24 is consistent with data previously published, showing that the *kynA* gene is overexpressed during the first hours of contact between *P. aeruginosa* and immune cells, then returning back to basal transcriptional activity [23].

Interestingly, many eukaryotic cells also produce metabolites from the kynurenine pathway, including anthranilate, 3-OH-anthranilate, kynurenine and kynurenic acid. These molecules possess well-described immunomodulatory functions in mammals [24]. Besides its implication in PQS synthesis, anthranilate, like its metabolite, 3-OH-anthranilate, supports immunomodulatory functions such as dendritic cell activation modulation or T-cell apoptosis [25–28]. Kynurenine and kynurenic acid modulate phagocytic cell functions [23] and recruitment [29], impair dendritic cell immunogenicity [30], and play a role in the polarization of the adaptive immune response [31].

Kynurenine and kynurenic acid also are ligands for the aryl hydrocarbon receptor, a crucial receptor for mucosal immunity [32]. Data generated in vivo may suggest that pulmonary infection with a bacterial strain highly expressing the kynurenine pathway enzymes could impair the equilibrium of the host’s tryptophan metabolism [23]. Thus, the kynurenine pathway could be involved in an inter-kingdom crosstalk between bacteria and their host, and may lead to an imbalance in the immune response to infection [33]. The finding of a trend toward decreased survival in mice infected with CHAΔkynU strain compared to those infected with CHAΔkynA strain, although not statistically significant, may support this hypothesis. However, *P. aeruginosa* possess several redundant virulence factors among which the type three secretion system leading to major cytotoxicity through secreted endotoxins, particularly in the CHA strain [34]. Considering the metabolites hypothetically involved in bacterial virulence, metabolites produced by the kynurenine pathway are not cytotoxic, even considering the involvement of the PQS, which has not been demonstrated during acute lung infection. Therefore, the role of bacterial kynurenine pathway might rather be an immunomodulatory role, difficult to evidence on outcome alone overwhelmingly due to major bacterial virulence factors [35].

Further research is needed to establish the potential interplay between bacterial and host tryptophan metabolites during infection, possibly paving the way to new immunomodulatory strategies.

**Conclusion**

*Pa* is able to produce multiple metabolites from tryptophan at sustained levels both ex vivo and in vivo through catabolism by the kynurenine pathway, including kynurenic acid and 3-OH-kynurenine, which was unknown to this date. The kynurenine pathway in *Pa* is critical to produce anthranilate, a crucial precursor of a *Pseudomonas* virulence factor, the *Pseudomonas* Quinolone Signal. When the anthranilate pathway is impaired, *Pa* tryptophan metabolism produces kynurenic acid. The involvement of this additional metabolic pathway during infection may be associated with impaired outcome. Because the kynurenine pathway metabolites are known to interfere with the innate and adaptive immune responses, bacterial kynurenine pathway may allow immunomodulatory interplay between bacteria and host. The existence of such interactions on the pathophysiology of *Pa* infection remains to be studied.

**Methods**

**Bacterial strains**

*Pa* wild type CHA strain used for experiments in this study, was isolated in 1993 from a cystic fibrosis patient four years after initial airway colonization. This strain
described in the article of Toussaint B. et al. [36] CHA has recently been included in the international reference panel of Pa strains. Thus, the CHA strain is maintained for the participating teams and was provided internally for the study. Pa wild type CHA strain and mutant strains CHAΔkynA and CHAΔkynU were grown in 5 ml of Luria Bertani broth non renewed medium (Sigma L3022, 10 g/L Tryptone, 5 g/L Yeast Extract and 5 g/L NaCl) at 37 °C with orbital shaking (350 rpm). Inoculum standardization was performed by optical density at 600 nm (OD_{600}, Ultrospec 10 Cell Density Meter, General Electrics, CT, USA) at an initial OD_{600} of 0.2.

Mutant construction
All PCR primers used in this study have been published previously [23]. They are based on the PAO1 genome sequence (http://www.pseudomonas.com). The mutants ΔkynA and ΔkynU in this study derived from the wild-type CHA Pa strain. Unmarked mutants were constructed by removing an internal fragment of coding sequence by means of allelic exchange, using a Cre-lox antibiotic marker recycling method as previously described [23]. Mutant strains had no significant growth differences compared with wild-type CHA [23].

Metabolites concentrations assessment
To assess kynurenine pathway metabolites production ex vivo, wild-type and mutants strains were grown in non-renewed LB medium. At H4, H6, H8 and H24, 500 µL of culture medium was sampled, centrifuged at 2000 g for 5 min, and immediately frozen at −80 °C for further analysis. To assess kynurenine pathway metabolites production in vivo, lungs were immediately frozen at −80 °C after extraction. Mouse lungs were homogenized in 500 µL of a half PBS - half RIPA buffer (ThermoFischer scientific) solution supplemented with protease inhibitor (Pierce™ Protease and Phosphatase Inhibitor Mini Tablets), then centrifuged (2000 g for 10 min) after resting 10 min on ice. Supernatants were immediately frozen at −80 °C for further analysis. Concentrations of tryptophan, kynurenine, kynurenic acid, 3-OH-kynurenine, anthranilate, 3-OH-anthranilate, xanthurenic acid, quinaldic acid and 8-OH-quinaldic acid were assayed, using an analytical procedure based on electrospray ionization liquid chromatography-tandem mass spectrometry (LC-ESI/MS/MS). This procedure was developed according to previously published methods, with slight modifications [37]. One hundred microliter of BAL, supernatants or culture medium were analyzed after the addition of 100 µL acetonitrile containing tryptophane-D5 at 50 000 nM, as an internal standard. The samples were mixed and centrifuged and the supernatant (100 µL) was added to deionized water (500 µL). Fifteen microliters of this mixture was injected onto an UPLC-MS/MS system (Xevo TQ-S Detector, Waters, Milford, USA) equipped with an Acquity HSS C18 column (Waters, Milford, USA). Ions of each analyzed compound were detected in a positive ion mode using multiple reaction monitoring. Chromalinks software (Waters) was used for data acquisition and processing.

Mouse strains
Age-matched animals in the C57BL/6 J background had free access to a standard laboratory chow diet in a half-day light cycle exposure and temperature-controlled specified-pathogen free environment as determined by the Federation for Laboratory Animal Science Associations recommendations. All animal experiments were performed in an accredited establishment (B 59 – 35010) according to the governmental guidelines N886/609/CEE.

Acute respiratory tract infection model
This model was induced by intranasal instillation of Pa. C57BL/6/J mice were lightly anesthetized with inhaled isoflurane (Forene Abbott, Queensborough, Kent, UK), after which 50 µl of the bacterial solution was administered intranasally (5.10^6 CFU per mouse, except for survival studies conducted with lethal inoculate: 1.10^7 CFU per mouse). Mice were killed at 12 or 24 h. In compliance with French animal care and use in investigational research guidelines, the mice were euthanized by lethal intraperitoneal injection of 0.3 ml of 5.47 % pentobarbital (Laboratoire CEVA, Libourne, France).

Bronchoalveolar lavage
Lungs from each experimental group were washed with a total of 1.5 ml of sterile phosphate-buffered saline (PBS). Recovered lavage fluid was pooled and centrifuged (300 g for 10 min); the cellular pellet was washed twice with PBS. Bronchoalveolar lavage (BAL) samples were filtered and immediately frozen at −80 °C after collection for metabolites concentrations assessment.

Statistical analysis
Statistical analysis was performed using Prism 6 software (GraphPad). Results are expressed as the mean ± standard deviation (SD) or ± standard error of the mean (SEM). One-way analysis of variance followed by multiple comparison tests or unpaired t-test were used for all comparisons except when otherwise indicated. Significance was accepted at P less than 0.05.

Abbreviations
BAL, bronchoalveolar lavage; KAT, kynurenine aminotransferase; KMO, kynurenine monoxygenase; KYNF, kynurenic formamidase; KYNU, kynureninase; Pa, Pseudomonas aeruginosa; PQS, pseudomonas quinolone signal; SD, standard deviation; SEM, standard error of the mean; TDO, tryptophan-2,3-dioxygenase
Additional file

**Additional file 1: Metabolites produced by the Pa kynurenine pathway of a clinical strain.** 1. Tryptophan (A), kynurenine (B), kynurenic acid (C), anthranilate (D), and 3-OH-kynurenine (E) concentrations in growth medium supernatants of a clinical strain as determined by UPLC-MS-MS. All data from one experiment in duplicate (PPTX 164 kb)

Acknowledgements
The authors thank « Vaincre La Mucoviscidose » for their contribution to the funding of this work. They are grateful to the Dr. T. Hubert and the D.H.U.R.E for animal breeding logistics.

Funding
This work was partially funded by the association "Vaincre La Mucoviscidose"

Availability of data and materials
All the data supporting our findings are contained within the manuscript. Supplemental informations can be obtained by sending email to the authors

Authors' contributions
PB, EK, BT and ALG conceived the study. PB, BH, CT, GJ, TG, MT performed experiments assisted by GJ. KF, BG, RD, DA, EF participated in study design and provided critical revisions. PB and EK analyzed the data and wrote the first draft of the manuscript. All authors discussed the results and commented on the manuscript. All authors have read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Information regarding all animal experiments was submitted to the French Ministry of Research and received Reference Number 00481.01 for the protocol entitled 'Study of immunity in a murine acute lung aggression model mediated by *P. aeruginosa*'.

Author details
1. Université Lille CHU Lille, EA 7366 - Recherche translationnelle: relations hôtes pathogènes, F-59000 Lille, France. 2. Laboratoire de Toxicologie - Pôle de Biologie-Pathologie-Genétique - CHRU de Lille - France, EA4483 - IMPECS, Université Lille Nord de France, Lille, France. 3. Translational host pathogen research group, Faculté de Médecine de Lille UDSL, Univ Lille Nord de France, Lille, France. 4. Faculté de Médecine de Lille UDSL, Univ Lille Nord de France, Lille, France. 5. Laboratoire TIMC-TherRex (UMR5525 CNRS-UGA) Université Grenoble Alpes, Faculté de médecine, La Tronche, France. 6. Unité médicale de Biochimie des enzymes et des protéines, CHUGA de Grenoble, CS10207, Grenoble 38043, Rhone alpes, France.

Received: 1 March 2016 Accepted: 30 June 2016

Published online: 08 July 2016

References
1. Hauser AR. Ventilator-associated pneumonia caused by *Pseudomonas aeruginosa*. Crit Care Med. 2012;40:2503–4.
2. Fujitani S, Sun H-Y, Yu VL, Weingarten JA. Pneumonia due to *Pseudomonas aeruginosa*: part I: epidemiology, clinical diagnosis, and source. Chest. 2011; 139:909–19.
3. Savoia D. New perspectives in the management of *Pseudomonas aeruginosa* infections. Future Microbiol. 2014;9:917–28.
4. Kumasov OQ, Jablonski LL, Polanuyer BD, Dorrestein PP, Begley TT, Osterman AA. Aerobic tryptophan degradation pathway in bacteria: novel kynurenine formamidase. FEMS Microbiol Lett. 2003;227:9–19.
5. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res. 2009;2:1–19.
6. Diggle SP, Winzer K, Chhabra SR, Worrall KE, Cámara M, Williams P. The *Pseudomonas aeruginosa* quinoline signal molecule overcomes the cell density-dependency of the quorum sensing hierarchy, regulates rhl-dependent genes at the onset of stationary phase and can be produced in the absence of LasR. Mol Microbiol. 2003;50:29–43.
7. Toyofuku M, Nakajima-Kambe T, Uchiyama H, Nomura N. The effect of a cell-to-cell communication molecule, *Pseudomonas* quinoline signal (PQS), produced by *P. aeruginosa* on other bacterial species. Microbes Environ. 2010;25:1–7.
8. Miller LL, Tsuitcha M, Adelberg EA. The transamination of kynurenine. J Biol Chem. 1953;203:205–11.
9. Crozier KR, Moran GR. Heterologous expression and purification of kynurenine-3-monooxygenase from *Pseudomonas* fluorescens strain 17400. Protein Expr Purif. 2007;51:32–34.
10. Knoten CA, Wells G, Coleman JP, Pesci EC. A conserved suppressor mutation in a tryptophan auxotroph results in dysregulation of *Pseudomonas* quinolone signal synthesis. J Bacteriol. 2014;196:2413–22.
11. Knoten CA, Hudson LL, Coleman JP, Farrow JM, Pesci EC, Kyri R. A Lrp/AsnC-Type Transcriptional Regulator, Directly Controls the Kynurenine Pathway in *Pseudomonas aeruginosa*. J Bacteriol. 2011;193:6567–75.
12. Palmer GC, Whiteley M. Metabolism and Pathogenicity of *Pseudomonas aeruginosa* Infections in the Lung of Individuals with Cystic Fibrosis. Microbiol Spectr. 2015;3(4):MBP-0003-2014.
13. Farrow JM, Pesci EC. Two Distinct Pathways Supply Anthranilate as a Precursor of the *Pseudomonas* Quinolone Signal. J Bacteriol. 2007;189:3425–33.
14. Yanofsky C. RNA-based regulation of genes of tryptophan synthesis and degradation, in bacteria. RNA. 2007;13:1141–54.
15. Stanier RY, Hayashi O, Tsuitcha M. The bacterial oxidation of tryptophan I. J Bacteriol. 1951;62(4):355-66.
16. Stanier RY, Hayashi O. The Bacterial Oxidation of Tryptophan: A Study in Comparative Biochemistry. Science. 1951;114:326–30.
17. Kumasov O, Goral V, Collarob K, Gerdes S, Anantha S, Osterman A, et al. NAD biosynthesis: identification of the tryptophan to quinolinate pathway in bacteria. Chem Biol. 2003;10:1195–204.
18. Bredenbruch F, Nintz M, Wray V, Morr M, Müller R, Häussler S. Biosynthetic pathway of *Pseudomonas aeruginosa* 4-hydroxy-2-alkylquinolines. J Bacteriol. 2005;187:3630–5.
19. Okada K, Angkawidjaja C, Koga Y, Takano K, Kanaya S. Characteristic features of kynurenine aminotransferase allosterically regulated by (alpha)-ketoglutarate in cooperation with kynurenine. PloS ONE. 2012;7:e40307.
20. Han Q, Fang J, Li J. Kynurenine aminotransferase and glutamine transaminase K of *Escherichia coli* cell identity with aspartate aminotransferase. Biochem J. 2001;360:167–22.
21. Han Q, Cai T, Tagle DA, Robinson H, Li J. Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II. Biosci Rep. 2008;28:205–15.
22. Barth AL, Pitt TL. The high amino-acid content of sputum from cystic fibrosis patients promotes growth of auxotrophic *Pseudomonas aeruginosa*. J Med Microbiol. 1996;45:110–9.
23. Genestet C, Le Gouellec A, Chaker H, Polack B, Guery B, Toussaint B, et al. Scavenging of reactive oxygen species by tryptophan metabolites helps *Pseudomonas aeruginosa* escape neutrophil killing. Free Radic Biol Med. 2014;73:400–10.
24. Mândi V, Vécei L. The kynurenine system and immunoregulation. J Neuroimmunol. 2011;199:197–209.
25. Austin CJD, Rendina LM. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy. Drug Discov Today. 2015;20:609–17.
26. Yeung AWS, Tenent AC, King NJC, Thomas SR. Role of indoleamine 2,3-dioxygenase in health and disease. Clin Sci. 2015;128:601–72.
27. Lee S-M, Lee Y-S, Choi J-H, Park S-G, Choi I-W, Joo Y-D, et al. Tryptophan metabolite 3-hydroxyanthranilic acid suppresses T cell responses by inhibiting dendritic cell activation. Int Immunopharmacol. 2013;17:721–6.
28. Lee S-M, Lee Y-S, Choi J-H, Park S-G, Choi I-W, Joo Y-D, et al. Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSH depletion. Immunol Lett. 2010;131:523–60.
29. Barth MC, Ahluwalia N, Anderson T, Hardy GJ, Sinha S, Alvarez-Cardona JA, et al. Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions. J Biol Chem. 2009;284:19189–95.
30. Nguyen NT, Kimura A, Nakahama T, Chinen I, Masuda K, Nohara K, et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A. 2010;107:19961–6.
31. Munn DH, Mellor AL. Indoleamine 2,3 dioxygenase and metabolic control of immune responses. Trends Immunol. 2013;34(3):137-43.
32. Moura-Alves P, Fae K, Houthuys E, Dorhoi A, Kreuchwig A, Furkert J, et al. AhR sensing of bacterial pigments regulates antibacterial defence. Nature. 2014;512:387–92.
33. Phillips RS. Structure, mechanism, and substrate specificity of kynureninase. Biochim Biophys Acta Proteins Proteomics. 2011;1814:1481–8.
34. Dacheux D, Attree I, Schneider C, Toussaint B. Cell death of human polymorphonuclear neutrophils induced by a Pseudomonas aeruginosa cystic fibrosis isolate requires a functional type III secretion system. Infect Immun. 1999;67:6164–7.
35. Sawa T. The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response. J Intensive Care. 2014;2:10.
36. Toussaint B, Delic-Attree I, Vignais PM. Pseudomonas aeruginosa contains an IHF-like protein that binds to the algD promoter. Biochem Biophys Res Commun. 1993;196:416–21.
37. Favennec M, Hennart B, Caiazzo R, Leloire A, Yengo L, Verbanck M, et al. The kynurenine pathway is activated in human obesity and shifted toward kynurenine monooxygenase activation. Obesity. 2015;23:2066–74.